Emerging Strategies in the Management of Chronic Fibrosing ILD Patients Who Have Contracted COVID-19

/ Print /
| ShareMore
/ Text Size +
11/9/20 2:00 pm EST
Virtual Webinar
United States


This webinar is jointly provided by MedNet, LLC. and Amedo, LLC.

cancernet Logo 2017                      amedcologo    

This activity is supported in part by an independent education grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Webinar Overview:

This activity will cover topics on the diagnosis, treatment, and management of patients with chronic fibrosing ILD and CF-ILD patients who have contracted COVID-19. Upon completion of this activity, participants should be better able to:

  • Evaluate the pathophysiology, prevalence, morbidity, mortality, signs, and symptoms of ILDs with a progressive fibrosing phenotype who have contracted COVID-19
  • Assess the potential of high-resolution computed tomography (HRCT) and quantitative computed tomography (CT) analysis as the primary tool for the diagnosis of progressive fibrosing phenotype
  • Cite emerging strategies to increase clinician's awareness of induced severe lung injury and acute respiratory distress syndrome (ARDS) in patients with progressive pulmonary fibrosis recovering from COVID 19

Target Audience

This activity is designed to meet the educational needs of pulmonologists, radiologists, pathologists, primary care physicians, physician assistants, registered nurses, nurse practitioners, pharmacists, fellows, residents, and other allied HCPs involved in the management of patients with CF-ILD.

Date and Time:

This webinar will be held on:

  • Monday, November 9, 2020 2:00 PM – 3:15 PM EDT


Justin M. Oldham, MD, MS
Assistant Professor of Medicine
Director, Interstitial Lung Disease Program
University of California at Davis
Davis, CA

Brian D. Southern, MD
Staff Physician, Respiratory Institute
Staff Scientist, Lerner Research Institute
Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Cleveland, OH


  • Physicians, Physician Assistants, Nurse Practitioners — maximum of 1.25 AMA PRA Category 1 Credit(s)™
  • Nurses — 1.25 Nursing Contact Hours
  • All other health care professionals completing this course will be issued a statement of participation.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet, LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation


Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Amedco LLC designates this enduring material activity for a maximum of 1.50 ANCC contact hours.

Nurse Practitioners

The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.50 hours.

Physician Assistants

AAPA accepts AMA PRA Category 1 Credit(s)™ for the PRA from organizations accredited by ACCME. Maximum of 1.50 hours.

Planners and Managers

  • Kamatham A. Naidu, PhD (MedNet, LLC), has no relevant financial relationships.
  • Brian Waggoner (MedNet, LLC) has no relevant financial relationships to disclose.
  • Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.

Certificates will be emailed to the participant.

Disclosure of Unlabeled Use

MedNet and Amedco require that faculty participating in any CME/CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


Amedco makes every effort to develop CME/CE activities that are scientifically based.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME/CE questions, please contact: Amedco at:

For questions regarding the content, please contact: MedNet at